WO2008050362A3 - Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies - Google Patents
Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies Download PDFInfo
- Publication number
- WO2008050362A3 WO2008050362A3 PCT/IT2007/000676 IT2007000676W WO2008050362A3 WO 2008050362 A3 WO2008050362 A3 WO 2008050362A3 IT 2007000676 W IT2007000676 W IT 2007000676W WO 2008050362 A3 WO2008050362 A3 WO 2008050362A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- allergies
- medicament
- prevention
- preparation
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002666562A CA2666562A1 (en) | 2006-10-27 | 2007-09-27 | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies |
US12/447,156 US20090270594A1 (en) | 2006-10-27 | 2007-09-27 | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies |
EA200900603A EA200900603A1 (en) | 2006-10-27 | 2007-09-27 | APPLICATION OF THYMOSINE ALPHA-1 FOR OBTAINING A MEDICINE FOR PREVENTION AND TREATMENT OF ALLERGIC REACTIONS |
JP2009534060A JP2010507649A (en) | 2006-10-27 | 2007-09-27 | Use of thymosin alpha 1 to prepare a medicament for the prevention and treatment of allergies |
AU2007310415A AU2007310415A1 (en) | 2006-10-27 | 2007-09-27 | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies |
BRPI0718019-5A BRPI0718019A2 (en) | 2006-10-27 | 2007-09-27 | USE OF ALPHA 1 TIMOSINE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF ALLERGIES. |
MX2009004237A MX2009004237A (en) | 2006-10-27 | 2007-09-27 | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies. |
EP07827727A EP2083847A2 (en) | 2006-10-27 | 2007-09-27 | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies |
IL198290A IL198290A0 (en) | 2006-10-27 | 2009-04-22 | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000583A ITRM20060583A1 (en) | 2006-10-27 | 2006-10-27 | USE OF THE TIMAMA ALFA 1 FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTION AND CARE OF ALLERGIES |
ITRM2006A000583 | 2006-10-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008050362A2 WO2008050362A2 (en) | 2008-05-02 |
WO2008050362A3 true WO2008050362A3 (en) | 2008-07-10 |
Family
ID=39322638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2007/000676 WO2008050362A2 (en) | 2006-10-27 | 2007-09-27 | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090270594A1 (en) |
EP (1) | EP2083847A2 (en) |
JP (1) | JP2010507649A (en) |
KR (1) | KR20090092267A (en) |
CN (1) | CN101626778A (en) |
AU (1) | AU2007310415A1 (en) |
BR (1) | BRPI0718019A2 (en) |
CA (1) | CA2666562A1 (en) |
EA (1) | EA200900603A1 (en) |
IL (1) | IL198290A0 (en) |
IT (1) | ITRM20060583A1 (en) |
MX (1) | MX2009004237A (en) |
WO (1) | WO2008050362A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087067A2 (en) * | 2003-03-28 | 2004-10-14 | Sciclone Pharmaceuticals, Inc. | Treatment of aspergillus infections with thymosin alpha 1 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4079127A (en) * | 1976-10-28 | 1978-03-14 | Board Of Regents Of The University Of Texas | Thymosin alpha 1 |
AR020102A1 (en) * | 1998-07-30 | 2002-04-10 | Ucb Sa | COMPOSITE FOR THE PREVENTION AND / OR TREATMENT OF ALLERGY; PHARMACEUTICAL COMPOSITION, COSMETIC COMPOSITION, COMPOSITION IN THE FORM OF DRINK, FOOD AND / OR FOOD FOR DOMESTIC ANIMALS THAT INCLUDES IT AND USE OF SUCH COMPOUND OR SUCH PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A FOOD |
US20060121029A1 (en) * | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
-
2006
- 2006-10-27 IT IT000583A patent/ITRM20060583A1/en unknown
-
2007
- 2007-09-27 KR KR1020097008098A patent/KR20090092267A/en not_active Application Discontinuation
- 2007-09-27 CN CN200780039959A patent/CN101626778A/en active Pending
- 2007-09-27 MX MX2009004237A patent/MX2009004237A/en not_active Application Discontinuation
- 2007-09-27 BR BRPI0718019-5A patent/BRPI0718019A2/en not_active IP Right Cessation
- 2007-09-27 WO PCT/IT2007/000676 patent/WO2008050362A2/en active Application Filing
- 2007-09-27 AU AU2007310415A patent/AU2007310415A1/en not_active Abandoned
- 2007-09-27 US US12/447,156 patent/US20090270594A1/en not_active Abandoned
- 2007-09-27 EP EP07827727A patent/EP2083847A2/en not_active Withdrawn
- 2007-09-27 EA EA200900603A patent/EA200900603A1/en unknown
- 2007-09-27 CA CA002666562A patent/CA2666562A1/en not_active Abandoned
- 2007-09-27 JP JP2009534060A patent/JP2010507649A/en active Pending
-
2009
- 2009-04-22 IL IL198290A patent/IL198290A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087067A2 (en) * | 2003-03-28 | 2004-10-14 | Sciclone Pharmaceuticals, Inc. | Treatment of aspergillus infections with thymosin alpha 1 |
Non-Patent Citations (6)
Title |
---|
AMLIE-LEFOND ET AL: "Innate immunity for biodefense: A strategy whose time has come", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 116, no. 6, 1 December 2005 (2005-12-01), pages 1334 - 1342, XP005198337, ISSN: 0091-6749 * |
C. MONTAGNOLI ET AL: "Immunity and Tolerance to Aspergillus Involve Functionally Distinct Regulatory T Cells and Tryptophan Catabolism", JOURNAL OF IMMUNOLOGY, vol. 176, no. 3, February 2006 (2006-02-01), pages 1712 - 1723, XP002478988 * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 31 January 1983 (1983-01-31), ZAWISZA E ET AL: "[Thymosin (TFX-Polfa) in the treatment of hay fever]", XP002479425, Database accession no. NLM6346287 * |
L. ROMANI ET AL: "Thymosin alpha 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance", BLOOD, vol. 108, no. 7, 1 October 2006 (2006-10-01), pages 2265 - 2274, XP002478987 * |
POLSKI TYGODNIK LEKARSKI (WARSAW, POLAND : 1960) 31 JAN 1983, vol. 38, no. 5, 31 January 1983 (1983-01-31), pages 153 - 154, ISSN: 0032-3756 * |
ROMANI L ET AL: "Thymosin 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 103, no. 11, 1 June 2004 (2004-06-01), pages 4232 - 4239, XP002903606, ISSN: 0006-4971 * |
Also Published As
Publication number | Publication date |
---|---|
IL198290A0 (en) | 2011-08-01 |
MX2009004237A (en) | 2009-07-07 |
ITRM20060583A1 (en) | 2008-04-28 |
KR20090092267A (en) | 2009-08-31 |
CA2666562A1 (en) | 2008-05-02 |
US20090270594A1 (en) | 2009-10-29 |
JP2010507649A (en) | 2010-03-11 |
EA200900603A1 (en) | 2009-10-30 |
EP2083847A2 (en) | 2009-08-05 |
BRPI0718019A2 (en) | 2013-11-19 |
AU2007310415A1 (en) | 2008-05-02 |
CN101626778A (en) | 2010-01-13 |
WO2008050362A2 (en) | 2008-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL177914A0 (en) | Use of indazolecarboxamide derivatives for the preparation of a medicament that is intended for the treatment and prevention of paludism | |
TWI369210B (en) | Use of lgg in the manufacture of a medicament for the prevention or treatment of respiratory allergies | |
EP1985302A4 (en) | Medicament for treatment of tumor and the use thereof | |
ZA200703601B (en) | Medicaments for the treatment or prevention of fibriotic diseases | |
EP1940361A4 (en) | Pharmaceutical dosage forms having immediate release and/or controlled release properties | |
HK1108168A1 (en) | Vaccine for prevention and treatment of hiv-infection | |
IL207439B (en) | Use of an anti-calcitonin gene-related peptide (cgrp) antagonist antibody for the manufacture of a medicament for the prevention and/or treatment of arthritic pain | |
EP2099449A4 (en) | Pharmaceutical composition for the treatment and prevention of diseases involving impotence | |
HK1129594A1 (en) | Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain | |
IL210589A (en) | Use of a tuberculosis rv2386c protein in the manufacture of a medicament for the treatment or prevention of tuberculosis | |
HK1244819A1 (en) | Foxm1 peptide and medicinal agent comprising the same | |
IL189162A0 (en) | Use of hydroxybenzoic acid ester and analogues for the manufacture of a medicament for the prevention and treatment of virus infection | |
EP2813223B8 (en) | Metal delivery agents and therapeutic uses of the same | |
HRP20130622T1 (en) | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis | |
EP1814567A4 (en) | Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections | |
GB2443336B (en) | Spiruchostatin analogues and their medicinal use | |
IL189270A0 (en) | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | |
ZA200800981B (en) | Use of SDF-1 for the treatment and/or prevention of neurological diseases | |
IL197766A0 (en) | Use of oritavancin for the prevention and treatment of anthrax | |
HK1111599A1 (en) | Pharmaceutical compositions for the treatment of cellulite | |
IL195955A0 (en) | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma | |
EP2231146A4 (en) | Pharmaceutical composition for the treatment and prevention of glaucoma | |
EP2005964A4 (en) | The medicament for treating hyperphospheremia and preparation thereof | |
WO2008157365A3 (en) | Vinylazacycloalkanes for treating neuropathic pain | |
WO2008050362A3 (en) | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780039959.4 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2666562 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097008098 Country of ref document: KR Ref document number: MX/A/2009/004237 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 198290 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2009534060 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007827727 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2881/CHENP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200900603 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007310415 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2007310415 Country of ref document: AU Date of ref document: 20070927 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07827727 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12447156 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0718019 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090427 |